NYSE:CTLT - Catalent Stock Price, Price Target & More

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) announced its earnings results on Tuesday, May, 1st. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.06. The business had revenue of $627.90 million for the quarter, compared to the consensus estimate of $610.47 million. Catalent had a net margin of 2.62% and a return on equity of 21.76%. Catalent's quarterly revenue was up 17.9% on a year-over-year basis. During the same period last year, the firm posted $0.38 earnings per share. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

Catalent issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

14 equities research analysts have issued 12-month target prices for Catalent's shares. Their forecasts range from $38.00 to $50.00. On average, they anticipate Catalent's stock price to reach $45.8182 in the next year. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Ratings for Catalent.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

News articles about CTLT stock have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.01%), State of Alaska Department of Revenue (0.01%) and Atria Investments LLC (0.01%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Atria Investments LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $42.86.

Catalent has a market capitalization of $5.79 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]